Immunovant, Inc.

Historical 13F Holders

Symbol
IMVT
CUSIP
45258J102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45258J102 since 12/18/2024, newest first.

Filer % of Class Filed
Deep Track Capital, LP 13G/A Amendment 1
4.6% 8/14/2026
Event 6/30/2026
Roivant Sciences Ltd. 13D/A Amendment 10 55.9% 12/12/2025
Event 12/12/2025
FMR LLC 13G/A Amendment 3
8.4% 11/5/2025
Event 9/30/2025
Roivant Sciences Ltd. 13D/A Amendment 9 56.9% 4/21/2025
Event 4/21/2025
Deep Track Capital, LP 13G
5.6% 3/26/2025
Event 3/19/2025
FMR LLC 13G/A Amendment 2
10.1% 3/7/2025
Event 2/28/2025
Roivant Sciences Ltd. 13D/A Amendment 8 56.9% 1/15/2025
Event 1/13/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 4.62 M $156 M
2026 Q2 242 114 M $4.34 B
2026 Q1 232 111 M $2.77 B
2025 Q4 215 109 M $2.78 B
2025 Q3 203 95.3 M $1.54 B
2025 Q2 184 96.3 M $1.54 B
2025 Q1 219 94.8 M $1.62 B
2024 Q4 213 82.3 M $2.04 B
2024 Q3 211 79.7 M $2.27 B
2024 Q2 223 76.5 M $2.02 B
2024 Q1 245 75.0 M $2.42 B
2023 Q4 264 72.0 M $3.03 B
2023 Q3 223 69.4 M $2.67 B
2023 Q2 162 56.9 M $1.08 B
2023 Q1 155 58.3 M $905 M
2022 Q4 143 59.7 M $1.06 B
2022 Q3 118 42.7 M $238 M
2022 Q2 100 40.1 M $157 M
2022 Q1 122 43.4 M $240 M
2021 Q4 131 38.0 M $324 M
2021 Q3 134 33.8 M $294 M
2021 Q2 134 38.6 M $408 M
2021 Q1 134 40.4 M $654 M
2020 Q4 151 40.6 M $1.88 B
2020 Q3 119 39.8 M $1.40 B
2020 Q2 90 28.6 M $696 M
2020 Q1 42 12.6 M $194 M
2019 Q4 26 11.6 M $176 M